Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Xgene Pharmaceutical

Explore full profile

Creating new, conjugated molecules that can be used to treat neurological disorders

ChinaFounded 2016Biotech & Life Sciences
Valuation $100–500M Latest valuation · 2026
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Xgene Pharmaceutical and the history behind them.

About Xgene Pharmaceutical

Xgene Pharmaceutical, Inc. is a late clinical stage, venture capital-backed international company specializing in the development of novel, multimodal, conjugated molecules aimed at treating neurological disorders. Utilizing proprietary linker technology, Xgene focuses on enhancing the efficacy and tolerability of pain therapeutics. The company serves the pharmaceutical and biotechnology sectors, targeting clients who require advanced therapeutic solutions for neurological conditions. Operating in the global market, Xgene's business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary treatments. Revenue is generated through venture capital funding, partnerships, and future sales of approved therapies.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2016
Headquarters
China
Open positions
None listed
Dealroom signal
18.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Links
Website

Latest news

Press, funding announcements and product moves mentioning Xgene Pharmaceutical.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Aug 2022 — — Taiwania Capital —
SERIES COther financing Nov 2021 $40M $160M Ping An Ventures · Yijing Capital · Neovision Capital · GSR United Capital —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Xgene Pharmaceutical website traffic

Latest recorded traffic for Xgene Pharmaceutical is 2.9K monthly website visits, up 81.3% over the last three months.

Latest monthly visits2.9K 3-month web change+81.3%
Monthly website visitsApr 2020–Jul 2026
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Teitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases Aarhus, Denmark Operational 25 $31M $123M
Tay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise Dundee, United Kingdom Operational
SPES Pharmaceuticals Inc.The company focuses on the research and development of improved specialty injectable products 505(b)(2)and complex generic drugs United States Operational
ExeVir BioCamelid-derived antibody therapies for infectious diseases Ghent, Belgium Operational
CV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments Belfast, United Kingdom Operational
Nucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine Oxford, United Kingdom Operational
Rosa BiotechAI-driven biosensing and diagnostics company providing outcome-focused biosensing for early disease diagnosis and for use in industrial biotechnology Bristol, United Kingdom Operational
Vincere BiosciencesVincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD) Cohasset, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • TF Capital
  • Ping An Ventures
  • Taiwania Capital

Series B and later3 investors entered at this stage

  • Neovision Capital
  • Yijing Capital
  • GSR United Capital

Talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Xgene Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Xgene Pharmaceutical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.